(Q33482122)

27 July 2017

A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects (English)

1 reference

27 July 2017

Daniel M Bloomfield

1

1 reference

27 July 2017

Rajesh Krishna

2

1 reference

27 July 2017

David Hreniuk

3

1 reference

27 July 2017

Lisa Hickey

4

1 reference

27 July 2017

Kalyan Ghosh

5

1 reference

27 July 2017

Arthur J Bergman

6

1 reference

27 July 2017

Jutta Miller

7

1 reference

27 July 2017

Maria J Gutierrez

8

1 reference

27 July 2017

Randall Stoltz

9

1 reference

27 July 2017

Keith M Gottesdiener

10

1 reference

27 July 2017

Gary A Herman

11

1 reference

27 July 2017

John A Wagner

12

1 reference

27 July 2017

1 August 2009

1 reference

The Journal of Clinical Pharmacology

27 July 2017

1 reference

27 July 2017

49

1 reference

27 July 2017

8

1 reference

27 July 2017

937-946

1 reference

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

27 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

The effect of moxifloxacin on QTc and implications for the design of thorough QT studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

Clinical assessment of drug-induced QT prolongation in association with heart rate changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337511

21 January 2018

Identifiers

DOI

10.1177/0091270009337511

1 reference

release_nzcdz2vzjzdrdkfc5hxikybpva

27 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nzcdz2vzjzdrdkfc5hxikybpva

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference